The registration for this event has passed. Check back soon for content you missed, post-event updates, as well as recommendations for future events you may be interested in.
Details
LMCE will be held on Oct 26-28 in Swiss Seoul Hotel and its theme is “Digital Transformation of Laboratory Medicine: Linchpin of Future Medical Value.” Illumina sponsors triple booths and education workshop as a gold sponsorship. For our education workshop, Prof. Kim will talk about “Experience of Validating Comprehensive Genome Profiling (CGP) ctDNA Assay for Clinical Use” and Eun-goo Jeong (Oncology Sr.Sales specialist, Illumina Korea) will talk about “Introduction of Illumina oncology research products -TruSight Oncology 500 portfolio.” This workshop is going to introduce how Illumina's TSO500 ctDNA and DRAGEN helps cancer research as well as clinical trials.
Please visit our booth and find out how Illumina can help your lab.
Education workshop#14
| Date & Time | Oct 27th 4:40 PM |
|---|---|
| Location | Room E(3F), Swiss Hotel |
| Speaker 1 | Eun-Goo Jeong (Sr. Sales specialist – Illumina Korea) |
| Talk title 1 | Introduction of Illumina oncology research products -TruSight oncology 500 portfolio |
| Abstract 1 | At Illumina, our mission is to improve human health by unlocking the power of the genome. In oncology field, we developed TruSight Oncology 500 portfolio, which enables pan-cancer comprehensive genomic profiling (CGP) for solid tumors from either blood or tissue biopsy samples. There are three assays in the portfolio, TruSight Oncology 500 and TruSight Oncology 500 High-Throughput for FFPE samples, as well as TruSight Oncology 500 ctDNA for blood plasma samples. They are all designed to analyze 523 cancer-relevant genes and identify relevant biomarkers in guidelines and clinical research, including the immuno-oncology markers TMB and MSI. In this session, I will provide detail information about TruSight Oncology 500 portfolio. |
| Speaker 2 | Young-gon Kim (Department of Laboratory Medicine and Genetics, Samsung Medical Center) |
| Talk title 2 | Experience of Validating Comprehensive Genome Profiling (CGP) ctDNA Assay for Clinical Use |
| Abstract 2 | Abstract: Liquid biopsy enables comprehensive analysis of circulating cell-free DNA (cfDNA) in plasma, providing a noninvasive approach for profiling solid tumors. TruSight Oncology 500 (TSO 500) ctDNA is a comprehensive genomic profiling platform which is capable of testing 523 genes associated with solid tumors including copy number variants, fusions, microsatellite instability, and tumor mutation burden. Validation of TSO 500 ctDNA was performed on the NovaSeqTM6000 and DRAGEN platform using various reference material and clinical specimen. OncoKBTMAPI was adjunctively used to annotate and filter variants provided by DRAGENTM. TSO 500 ctDNA is an effective and versatile assay for clinical use. |
- Date & Time
- 26 Oct. 2022 – 28 Oct. 2022
- Location
- Room E(3F), Swiss Hotel
- Korea South
- Asia
- Topic
- Cancer research, Oncology, Reproductive health, Software & informatics, Library preparation kits, Microbial genomics